

1 **Biomonitoring of perfluoroalkyl and polyfluoroalkyl substances (PFAS) from the Survey of**
2 **the Health of Wisconsin (SHOW) 2014-2016 and comparison with the National Health and**
3 **Nutrition Examination Survey (NHANES)**

4
5 Amy Schultz PhD MS¹, Noel Stanton MS², Rachel Pomazal¹, Meshel Lange², Roy Irving PhD³,
6 Jonathan Meiman PhD³, Brandon Shelton², Kristen CM Malecki PhD MPH^{1,4}
7

8 ¹Survey of the Health of Wisconsin (SHOW), University of Wisconsin Madison ²Wisconsin
9 State Lab of Hygiene (WSLH) ³Wisconsin Department of Health Services ⁴University of Illinois
10 at Chicago School of Public Health
11

12 Corresponding Author: Amy Schultz PhD MS aaschultz4@show.wisc.edu
13

14 Funding: Funding for SHOW comes from the Wisconsin Division of Public Health, the
15 Wisconsin Partnership Program (PERC) Award (223 PRJ 25DJ), the National Institutes of
16 Health's Clinical and Translational Science Award (5UL 1RR025011), and the National Heart
17 Lung and Blood Institute (1 RC2 HL101468) and a core grant to the Center for Demography
18 and Ecology at the University of Wisconsin-Madison (P2C HD047873).
19

20 **Abstract**

21 **Background:** Per- and polyfluoroalkyl substances (PFAS) are a growing class of manufactured
22 chemical compounds found in a variety of consumer products. PFAS have become ubiquitous in
23 the environment and were found in many humans sampled in the United States (U.S.). Yet,
24 significant gaps in understanding statewide level exposures to PFAS remain.

25 **Objective:** The goals of this study are to establish a baseline of exposure at the state level by
26 measuring PFAS serum levels among a representative sample of Wisconsin residents and
27 compare to United States National Health and Nutrition Examination Survey (NHANES).

28 **Methods:** The study sample included 605 adults (18+ years of age) selected from the 2014-2016
29 sample of the Survey of the Health of Wisconsin (SHOW). Thirty-eight PFAS serum
30 concentrations were measured using high-pressure liquid chromatography coupled with tandem
31 mass spectrometric detection (HPLC-MS/MS) and geometric means presented. Weighted
32 geometric mean serum values of eight PFAS analytes from SHOW were compared to U.S.
33 national levels from the NHANES 2015-2016 sample (PFOS, PFOA, PFNA, PFHxS, PFHpS,
34 PFDA, PFUnDA), and the 2017-2018 sample for Me-PFOSA, PFHPS using the Wilcoxon rank-
35 sum test.

36 **Results:** Over 96% of SHOW participants had positive results for PFOS, PFHxS, PFHpS,
37 PFDA, PFNA, and PFOA. In general, SHOW participants had lower serum levels across all
38 PFAS when compared to NHANES. Serum levels increased with age and were higher among
39 males and whites. These trends were seen in NHANES, except non-whites had higher PFAS
40 levels at higher percentiles.

41 **Significance:** Wisconsin residents may have a lower overall body burden of some PFAS
42 compounds compared to those seen by a nationally representative sample. Additional testing and
43 characterization may be needed in Wisconsin, particularly among non-whites and low
44 socioeconomic status, for which the SHOW sample had less representation compared to
45 NHANES.

46
47 **Keywords:** Exposure assessment, PFAS, Per and Poly fluoroalkyl substances, population-based
48

49 **Impact Statement:** The present study conducts biomonitoring of 38 PFAS in the state of
50 Wisconsin and suggests that while most residents of Wisconsin have detectable levels of PFAS
51 in their blood serum, they may have a lower body burden of some PFAS compared to a
52 nationally representative sample. Older adults, males, and whites may have a higher body burden
53 of PFAS relative to other groups both in Wisconsin and the wider United States.

54 55 **1. Introduction**

56 Per- and polyfluoroalkyl substances (PFAS) are a large family of manufactured, or human-made,
57 fluorinated compounds produced for a variety of consumer products. PFAS are known as legacy
58 chemicals because of their long half-life and ability to accumulate in the environment, as well as
59 in animal and human blood serum and tissue [1-2]. The water and oil repellent properties of
60 PFAS make them desirable for use as flame retardants and other common consumer products [2].
61 PFAS are highly stable compounds that not only repel water, oils, and lipids, but bind to proteins
62 [3], and their strong carbon-fluorine bonds do not readily degrade. Therefore, some PFAS
63 compounds can remain within all trophic levels for years or decades [4].
64

65 The stability of these compounds makes mitigation and removal of PFAS from the environment
66 challenging. Environmental contamination sites have been identified for PFAS, which often
67 arise from industrial production or agricultural practices using contaminated fertilizer [5]. Over
68 time, PFAS leach into groundwater, surface waters, and soil. Major exposure pathways for PFAS
69 in humans include consumption of contaminated food, especially fish and red meat [6]. Other
70 sources of human exposure to PFAS include drinking water, contact with consumer products,
71 and ingestion of dust particles [2].

72
73 Due to the widespread use of PFAS, recent environmental assessments have found them to be
74 ubiquitous in the environment and in humans [7]. The U.S. Centers for Disease Control (CDC)
75 biomonitoring of PFAS in the U.S. general population found nearly all the n=7991 U.S. residents
76 tested via the 2011-2018 NHANES survey had detectable levels of one or more of the most
77 studied long-chain PFAS: PFOA, PFOS, PFHxS, and PFNA [8]. This raised public health
78 concerns, especially as PFAS research finds more associations between PFAS exposure and
79 adverse human health effects [9]. Exposure to PFAS has been associated with cancer [10],
80 higher cholesterol [11], liver enzyme changes [12], lower infant birth weight [13], decreased
81 pediatric vaccine response [14], increased risk of gestational hypertension or pre-eclampsia [15],
82 and immune suppression [16].

83
84 While PFOS and PFOA went largely unregulated for decades, in 2002 the U.S. Environmental
85 Protection Agency (EPA) began to regulate PFAS, requiring manufacturers to notify the EPA of
86 the manufacture or import of 13, and later 75, of the compounds [17]. Long-chain PFAS are still
87 used in imported products from developing countries [18,19]. In June 2022, the EPA set a non-
88 enforceable lifetime health advisory for PFOS and PFOA in drinking water to 0.02 and 0.004
89 parts per trillion, respectively [20]. A handful of states, including Wisconsin, have adopted the
90 2016 standard as the statewide regulatory standard for at least one PFAS compound [21]. This is
91 a rapidly evolving regulatory landscape, with some states making recommendations more
92 stringent than the EPA standard, and others making no recommendations at all [21]. However,
93 there are an estimated 4000 PFAS compounds [17] produced by industry, no biomonitoring or
94 epidemiological research on the vast majority of PFAS. Although long-chain PFASs (PFOA and
95 PFAS) have been phased out of production in the U.S. and Canada, they are replaced by short-
96 chain PFAS in industrial production. Additional biomonitoring and research are needed to
97 understand how short-chain PFAS affect human health [22].

98
99 CDC biomonitoring of PFAS in the U.S. general population, and several other biomonitoring
100 studies have emerged in the U.S. over the last decade. Little biomonitoring yet to be seen in the
101 Upper Midwest and central region of the U.S. [23-27]. With NHANES data, the CDC established
102 baseline exposure data for PFAS in the U.S., but the scale of the survey lacks the granularity
103 needed to understand PFAS within smaller regions and demographic strata at the state or local
104 level. The other community-based and localized biomonitoring studies to-date are not sampled in
105 such a way to provide representation of PFAS exposure across an entire state. This study begins
106 to fill this data gap by providing baseline PFAS levels representative of residents in the state of
107 Wisconsin. The study uses serum samples from The Survey of the Health of Wisconsin (SHOW)
108 cohort, the only statewide representative health survey in the U.S. modeled after NHANES.

109
110 In Wisconsin, PFAS have been found in groundwater supplies exceeding health-based
111 recommendations [28]. Not only are there several contamination sites in Wisconsin, including

112 the Marinette and Peshtigo areas in Marinette county due to production and testing of aqueous
113 film-forming foams (AFFF) [29], but it's history in paper production and known PCB and
114 mercury contamination water ways from paper mills [30-32], in conjunction with agricultural use
115 of wastewater sludge on crop fields, provide a landscape upon which residents may be at risk of
116 PFAS exposure [33-34]. PFAS has been detected in not only groundwater, but in milk raised and
117 produced in Wisconsin, the second largest dairy producing state [33]. Eighteen different PFAS
118 compounds were detected in well samples in Madison, Wisconsin in domestic, municipal, and
119 agricultural wells [35]. Furthermore, Wisconsin's variable geography (forested, agricultural, and
120 varying levels of urbanicity) and demographics are reasonably comparable to that of the broader
121 United States in age structure, gender, and race [36].

122
123 The Wisconsin State Laboratory of Hygiene (WSLH) developed a new method to detect PFAS
124 compounds at lower concentrations which increases the number of compounds available for
125 assessment than have been used by many previous biomonitoring studies. In this study, we first
126 examined an expanded list of PFAS compounds analyzed them using high-pressure liquid
127 chromatography coupled with tandem mass spectrometric detection (HPLC-MS/MS) and, where
128 we were able to, compared SHOW PFAS serum levels to those PFAS serum levels of a
129 nationally representative sample of the United States (NHANES). While other studies have
130 drawn comparisons to NHANES PFAS levels, to our knowledge, no other statewide
131 representative samples have compared PFAS levels to NHANES.

132

133 **2. Methods**

134 **2.1 Survey of the Health of Wisconsin (SHOW)**

135 Survey data and biospecimens came from the 2014-2016 Survey of the Health of Wisconsin
136 (SHOW) statewide representative sample of adults ages 18 and older (n=1957). Details on the
137 SHOW sampling frame, recruitment, and methods are described elsewhere [37]. In brief, the
138 SHOW 2014–2016 cohort was designed as a three-year sample. A three-stage cluster-sampling
139 approach was employed. One county per strata was randomly selected within the strata of county
140 mortality rates, followed by random selection of census block groups by poverty status strata.
141 Then 30–35 residential households were randomly selected via US postal service listings.

142 Housed within the Department of Population Health Sciences at the University of Wisconsin-
143 Madison, SHOW conducts statewide population-based recruitment and longitudinal follow-up of
144 a representative sample of state residents SHOW is unique in that it is the only statewide
145 household-based examination survey in the United States and offers an abundance of survey and
146 physical measurement data upon which to characterize PFAS exposure within our sample.
147 Modeled after the CDC's NHANES, its survey data includes demographics (age, gender,
148 education, income, race), behaviors (smoking, diet), occupation (military service, firefighter),
149 housing (type and age of residence), drinking water characteristics (private well vs. municipal,
150 depth of private well, consumption pattern, treatment/filter use), diet (fish, dairy) and chronic
151 health conditions (cancer, diabetes, hypertension, obesity). In addition, participant households
152 span rural, urban and suburban settings and are geocoded to allow for linkages to contextual
153 environmental data, including potential PFAS sources (landfills, industrial and municipal
154 wastewater facilities, agricultural fields).

155 Households are randomly selected from commercially available US Postal Service residential
156 address listings using a random probability-based sampling procedure and SHOW trained
157 interviewers conduct in-home visits upon which they gather health information via computer
158 assisted personal interview (CAPI). Participants also complete a self-administered paper
159 questionnaire. Following an in-home visit, participants visit a collection site near their home
160 where phlebotomists measure blood pressure, weight, height, waist and hip circumference,
161 respiratory function, and collect venous blood and urine samples. Several tubes of venous blood
162 (about 55–60 ml in total) are immediately processed for serum and plasma, aliquoted into
163 cryovials and frozen at –80C. SHOW participants consent to the use of biospecimens for
164 unspecified research. The core SHOW study and this study is approved by the University of
165 Wisconsin Health Sciences Institutional Review Board and all biosecurity and institutional safety
166 procedures are HIPAA compliant.

167 For this study, a subset of (n=605) participants were selected at random from SHOW's 2014–
168 2016 statewide representative sample. For this retrospective sample analysis, a single random
169 sample of adults 18+ (n=50; stratified by race, sex, age), was pulled from each of 12 counties
170 representing each of 5 health regions in the state. Only individuals with stored serum were
171 included when selecting the study sample. This allows for the assessment of historic PFAS
172 exposures across Wisconsin and accelerates the ability to observe time-dependent trends in
173 exposures when prospective sampling is performed. An additional sample was pulled per health
174 region as substitution in case any samples were not viable for PFAS analyses. Serum samples
175 were extracted from SHOW's freezer and sent to the Wisconsin State Laboratory of Hygiene on
176 dry ice for PFAS analyses.

177 **2.3 PFAS Sample Analysis**

178 The PFAS analyses were performed by the Wisconsin State Lab of Hygiene (WSLH) using high-
179 pressure liquid chromatography coupled with tandem mass spectrometric detection (HPLC-
180 MS/MS). The 38 PFAS compounds tested were selected based on several considerations,
181 including, (1) cover the spectrum of compounds to look for class-specific bioaccumulation, (2)
182 include compounds most often used in products and tested by CDC in NHANES, (3) include
183 both short and long chain PFAS to assess differences by type, (4) include emerging compound
184 classes for which we have little data, (5) consider potential toxicity estimates, and (6) limited by
185 the availability of suitable materials to assure reliable measurement.

186 The WSLH test method was adapted primarily from a method developed by Minnesota Dept. of
187 Public Health [38], with elements from CDC Method 6304.08 [39], the New York State Dept. of
188 Health [40], and the Michigan Dept. of Community Health [41]. Several of these documents are
189 laboratory manuals, some shared privately between colleagues. Sample preparation involved
190 spiking aliquots of serum with an isotopically labeled PFAS mixture. Acetonitrile was added to
191 precipitate proteins, followed by vortex mixing. Samples were then centrifuged, the supernatant
192 transferred to a 96-well plate, and evaporated to a volume of 100-200 mL.

193 Prepared samples were injected on an Agilent 1290 Infinity UPLC (Santa Clara, CA) equipped
194 with a BEH C18 1.7mm 2.1X50mm Column (Waters, Milford, MA). Good chromatographic
195 separation was achieved using a reverse phase gradient, with a 20 minute run time at 45°C.
196 Sample detection and quantification was achieved with a Sciex 4500 MS/MS system (Toronto,

197 CA), employing multiple reaction mode (MRM) scanning with negative polarity turbospray
198 ionization. Q1 and Q3 masses, declustering Potential (DP), collision energy (CE) and collision
199 cell exit potential (CXP) values for each MRM transition were optimized by parameter ramping
200 experiments with direct standard solution infusion to the source. Sciex Analyst version 1.6.3 was
201 used for data acquisition and results calculation.

202 Method quality control characteristics included a method blank and seven standard linear
203 calibration standards ($r \geq 0.995$). Standards were verified using a second source material.
204 Analytical signal/noise for S_i was required to be ≥ 10 . Ion confirmation ratio for samples was
205 required to fall within $\pm 30\%$ of the mean ratio of the standards, with exceptions for PFOS,
206 FOSA, PFDA, PFNS, 11Cl-PF3OUdS, PFHxA, PFTTrDA, PFDS, PFTeDA, and 8:2 diPAP,
207 which were widened to $\pm 40\%$ based on poor confirmation ion sensitivity. Method detection
208 limits varied considerably by compound, as did the upper quantification limits, but compare
209 favorably with NHANES quantification thresholds for those compounds. Three levels of
210 analytical controls were measured in every analytical run, and acceptable control values
211 bracketed all test samples. Method validation also included precision, analytical measurement
212 range, and spike recovery assessment. Additional details on the analytical method area and
213 observations on compounds not comparable with NHANES are in preparation.

214 **2.4 National Health and Nutrition Examination Survey (NHANES)**

215 NHANES is an ongoing national cross-sectional survey administered by the National Center of
216 Health Statistics (NCHS) within the CDC. NHANES uses a multistage cluster sampling
217 approach to examine a study population that is representative of the United States' non-
218 institutionalized population. Blood samples are taken from all NHANES participants 12 years of
219 age and older. Approximately 2,000 of these samples were analyzed for several PFAS
220 compounds in each cycle. The NHANES 2015-2016 sample intentionally oversamples Hispanic,
221 Non-Hispanic black, Non-Hispanic Asian, Non-Hispanic white and others at or below 185
222 percent of the Department of Health and Human Services (HHS) poverty guidelines, and Non-
223 Hispanic white and other people aged 80 years and older. NHANES releases publicly available
224 laboratory and demographic data on these participants. Education and smoking status for
225 adolescents (age 12-19) is considered sensitive data and not included in public use datasets.
226 Documentation for NHANES data includes detailed laboratory methods [42]. For this study,
227 SHOW study sample PFAS serum levels were compared with those from the National Health
228 and Nutrition Examination Survey (NHANES) 2015-2016 sample (n=1829) for all
229 corresponding samples. However, given that NHANES did not sample the entire suite of
230 compounds in this study, the 2017-2018 (n=1862) samples were compared for select compounds
231 (ME-PFOSA and PFHPS).

232 **2.5 Demographics**

233 Self-reported demographics data for gender, age, race/ethnicity, highest education level attained,
234 and income were collected by CAPI. Smoking status data were obtained through a self-
235 administered questionnaire (SAQ) for the Wisconsin Sample and personal interview for
236 NHANES. Income/poverty ratio was calculated by dividing the midpoint of reported household
237 income range by HHS poverty guidelines, which is calculated by the number of people supported
238 by that income [43]. Body mass index (BMI) (kg/m^2) was calculated using WHO standards by

239 dividing measured height (cm) by 100, and squaring that value, and then dividing weight (kg) by
240 that value. SHOW and NHANES participants were stratified by gender, age, and race for
241 analysis of PFAS serum levels. Age groups were determined by generational changes (18-39, 40-
242 59, 60+), and race was grouped by non-Hispanic white and non-white. Minors in the NHANES
243 samples were excluded from the final analysis.

244 **2.6 Statistical Analyses**

245 All statistical analyses were performed using SAS v9.4. All thirty-eight PFAS compounds were
246 reported for SHOW using the LLOD available from the WSLH assays. However, only
247 compounds analyzed in both SHOW and available in NHANES public use laboratory data were
248 included in comparative data analysis, and only compounds with more than 15% positivity in the
249 SHOW sample could be reliably compared to NHANES. Thus, weighted geometric means for 8
250 PFAS compounds, as well as weighted geometric means for the 50th, 75th, 90th, and 95th percentiles
251 and their corresponding 95% confidence intervals were calculated for SHOW and NHANES (see
252 Table 2 for complete list of PFAS). The lower limit of detection (LLOD) for all compounds in
253 NHANES was 0.1 ng/mL, with values lower than the LLOD set to 0.1 divided by the square root
254 of 2, or approximately 0.07. The LLODs for SHOW participants were different from 0.1, but to
255 make direct comparisons, all PFAS compounds within SHOW were assigned the same LLOD as
256 NHANES for comparison analyses. Therefore, weighted geometric means differ for SHOW in
257 the comparison tables with NHANES, when compared to findings from SHOW with the LLOD
258 from WSLH, unaltered to match NHANES.

259 PFOS and PFOA were analyzed as the sum of their linear and branched isomers, consistent with
260 NHANES methods. Data from minors ages 12-17 in the NHANES sample were used to validate
261 data analysis methods against published NHANES data tables, but minors were not included in
262 the final analysis as all SHOW participants were over the age of 18. Geometric means of serum
263 levels and corresponding 95% confidence intervals were calculated for all compounds and
264 compared between SHOW and NHANES. Both NHANES and SHOW geometric means were
265 calculated using subsample weights, and domains of gender, age, and race.

266 While overall and demographic strata comparisons of PFAS serum levels in SHOW vs.
267 NHANES are weighted, due to the different complexities of sampling in both SHOW and
268 NHANES, unweighted comparisons of PFAS serum concentrations were evaluated using the
269 Wilcoxon rank-sum test to test difference. Compounds detected above the limit of detection in
270 fewer than 50% of individuals were not included in further analysis comparisons with NHANES.

271

272 **3. Results**

273 **3.1 Study Sample**

274 Descriptive characteristics of the SHOW 2014-2016 subsample compared with NHANES 2015-
275 2016 and NHANES 2017-2018 samples are presented in Table 1. The SHOW study sample is
276 comparable to NHANES in terms of gender and age distribution. There are slightly more females
277 (50.7%) than males in SHOW; similar in NHANES (51.5-51.6%). The SHOW sample differs
278 from NHANES most in terms of racial diversity. The SHOW consists of 81.3% non-Hispanic
279 white, much higher when compared with NHANES where 62.3-62.9% are non-Hispanic white.
280 SHOW also had slightly more participants with >3 income to poverty ratio, fewer smokers, and

281 more with a BMI > 30 (Table 1). SHOW participants also tended to be more educated than
282 NHANES participants on average, with 27.1% of SHOW participants reporting high
283 school/GED or less in SHOW, compared with 34.2% in NHANES.

284 **3.2 Prevalence of detectable serum PFAS levels**

285 Table 2 depicts the detection limit and summary statistics for the number of positive results,
286 geometric mean, minimum and maximums for all 38 PFAS compounds. Nine of the 38 PFAS
287 compounds were detected in at least 50% of SHOW participants (PFOS, PFOA, PFNA, PFHxS,
288 PFDA, PFHpS, PFUnDA, PFHpA, PFPeS) (Table 2). More than 96% of SHOW participants had
289 serum levels above the lower limit of detection for six PFAS analytes, PFOS, PFOA, PFNA,
290 PFHxS, PFDA, and PFHpS with geometric mean values being 4.513, 1.196, 0.452, 1.138, 0.142,
291 and 0.168 ng/mL, respectively. Eight PFAS compounds were below the limit of detection in
292 100% of the study sample (NMeFOSA, N-EtFOSE, 6:2 FTSA, PFTriA, PFODA, DONA,
293 PFMPA, PFMBA). SHOW participants had much higher levels of PFOS compared to other
294 compounds, with a whole sample geometric mean of 4.513 µg/L (Table 2).

295 **3.3 PFAS Comparison of SHOW to NHANES by demographics**

296 Table 3 depicts comparisons in geometric means and percentiles between the entire SHOW and
297 NHANES samples where LLOD has been adjusted for SHOW to match NHANES. Tables 4-6
298 (and supplementary tables 1-5) depict geometric means and percentiles comparing SHOW and
299 NHANES by demographic strata. Weighted geometric means of PFAS serum levels were
300 slightly higher among NHANES study sample compared to SHOW for PFOS, PFOA, PFNA,
301 PFHxS, PFDA, and PFHPS. However, only PFOA and PFNA were statistically higher among
302 NHANES compared SHOW ($p < 0.001$). Most notable differences in weighted geometric means
303 were seen for PFHPS, PFOA, and PFNA, where NHANES serum samples were 35.3%, 32.5%,
304 and 31.1% higher than in SHOW, respectively. PFDA, PFOS, and PFHxS weighted geometric
305 mean serum levels were 14.3%, 10.2%, 7.0% higher in NHANES when compared to SHOW.
306 PFOS weighted geometric means (95% CI) were highest of all PFAS compounds in both study
307 samples; 4.51 (4.18-4.87) in SHOW compared to 4.97 (4.71-5.25) in NHANES.

308 Serum levels increased with age in both SHOW and NHANES for all 6 PFAS compounds. In
309 SHOW, 18–39-year-olds had a PFOS geometric mean of 3.13 (2.71-3.62) compared to 60+ year-
310 olds 7.39 (6.72-8.31); whereas the 95th percentile was 8.80 (7.70-10.20) for 18–39-year-olds and
311 26.3 (21.8-30.5) for 60+ year-olds. Similar trends held for NHANES.

312 In SHOW, males had higher serum levels of PFOS, PFOA, PFNA, PFHxS, and PFHPS than
313 females; a difference in weighted geometric mean of 1.06, 0.1, 0.03, and 0.5 ng/mL,
314 respectively. Levels did not differ by sex for PFDA; these trends by sex were seen in both the
315 NHANES and SHOW samples for all PFAS.

316 Weighted geometric mean serum levels were higher among whites (non-Hispanic) in SHOW and
317 NHANES for PFOA, PFOS, PFHxS and PFHPS when compared to nonwhites. These trends
318 held in the 50-95th percentiles for SHOW, but for NHANES, these trends were opposite at the
319 higher percentiles (90th and 95th) for PFHPS and PFOS. PFHPS was 40% higher, and PFOS was
320 20% higher, among nonwhites compared to whites (non-Hispanic) in NHANES at the 95th
321 percentile.

327
328 SHOW and NHANES samples were largely comparable for other PFAS compounds, (see Supp.
329 Tables 1-5), albeit low levels of detection were seen for both SHOW and NHANES for these
330 additional PFAS compounds.

331 332 **4. Discussion**

333 To our knowledge this is the first study to characterize PFAS serum levels among a statewide
334 representative sample and compare levels to those of NHANES. This study expanded
335 biomonitoring to a panel of 38 PFAS compounds and detected concentrations in serum with
336 LLOD lower than many prior studies. The study leveraged the SHOW cohort, the only statewide
337 adult cohort in the U.S. modeled after NHANES to provide baseline data for the state of
338 Wisconsin. Beyond NHANES, current understanding of human serum PFAS levels come from
339 specific sub-population cohorts (i.e. occupational, maternal-child cohorts) [23,44], high-risk or
340 localized communities near contamination [24-26]. While baseline PFAS levels are known at a
341 national scale using NHANES, those data lack the granularity needed at the state level and
342 within subregions and strata in a state. SHOW's statewide cohort provides PFAS serum
343 prevalence for the state, and within subpopulations and communities, spanning different
344 demographics, socio-economic backgrounds, and neighborhood environments. This study fills a
345 data gap and allows for identification of previously unknown high-risk areas or sub-populations
346 upon which researchers and state health officials can target additional biomonitoring and testing.

347
348 Among the 38 PFAS analytes tested, six were widely prevalent among SHOW; more than 96%
349 of SHOW participants had detectable serum levels of PFOS, PFOA, PFNA, PFHxS, PFDA, and
350 PFHpS. These findings align with what other studies have found. For example, Yu and
351 colleagues conducted statewide testing in New Jersey from remnant sera from clinical labs and
352 blood banks (n=1030) and of the 12 PFAS compounds tested, PFOA, PFNA, PFOS, and PFHxS
353 were the ones detected in over 99% of the study population with geometric means greater than
354 0.5 µg/L [44]. Even among high-risk or communities near contamination sites, the same PFAS
355 compounds were the most widespread, and with the highest geometric means. Among n=192
356 claimants from class-action lawsuit in Paulsboro, New Jersey, who lived near a contamination
357 site, of 13 PFAS compounds tested, PFOS, PFOA, PFNA and PFHxS had the highest
358 prevalence, with over 70% with detectable levels [24]. This held true in other states, such as the
359 communities tested near military bases in Pennsylvania [45] where PFOS, PFOA, PFHxS, and
360 PFNA were highest and most prevalent of the 11 PFAS tested, and those in the Annison
361 Community Health Survey living near a high-risk manufacturing site in Alabama, where among
362 the 8 PFAS tested, PFOS, PFNA, PFOA, and PFHxS were detected in >96% [26].

363
364 Geometric means and trends cross demographic strata and percentiles among SHOW were like
365 those seen in NHANES. Yet, NHANES consistently had slightly higher geometric means for all
366 6 main PFAS compounds analyzed (PFOS, PFOA, PFNA, PFDA, PFHxS, PFHPS), even though
367 only PFHPS, PFDA, and PFNA were statistically significantly different at 0.05 level. While we
368 are unsure why this is the case, it may be that Wisconsin has less exposure to PFAS in the
369 environment and/or in products used by its residents. PFOS was among the most prevalent of the
370 PFAS compounds measured among the SHOW sample and had the highest geometric mean and
371 percentile concentrations. This was also true among NHANES, as was seen among nearly all
372 prior biomonitoring studies, including those who tested high-risk populations such as firefighters

373 and communities near contamination sites [24-26,46,47]. Higher serum concentrations levels of
374 PFOS are not surprising due its (and PFOA's) U.S. production since the 1940s, which peaked
375 between 1970 and 2002. PFOS and PFOA were the most widely used PFAS compounds in
376 consumer products up until recently [10].

377
378 Males and older age were associated with higher levels of PFAS in SHOW across all PFAS
379 compounds analyzed, with few exceptions. This trend held true in NHANES, and in other
380 studies. For example, communities tested near military bases in Pennsylvania [45] found PFOS,
381 PFOA, and PFHxS were all higher in males, and all increased with age. Those tested living
382 nearby a PFAS manufacturing facility in New Jersey saw similar increases in PFAS
383 concentration with age and were higher among males [24]. Olsen et al. similarly found sex and
384 age trends as seen in NHANES [48]. Lower concentrations in females may be explained by
385 greater excretion rate through menstrual blood loss and lactation [49]. We would expect PFAS
386 concentrations to be higher among older adults compared to younger adults due to the
387 bioaccumulation that occurs as one ages, in conjunction with potentially higher exposure >10
388 years ago before PFAS started being manufactured overseas and phased out of products.

389
390 Both SHOW and NHANES saw similar trends in PFAS concentrations by race, with non-
391 Hispanic whites having higher geometric means compared to non-whites. While in SHOW, this
392 trend remained across percentiles, the NHANES sample saw opposite trends at the 90th and 95th
393 percentile for some compounds (PFHPS, PFDA, PFNA, PFOS), where non-whites had higher
394 PFAS concentrations than non-Hispanic whites. This difference may be due to the small non-
395 white sample in SHOW and therefore an inability to adequately capture potential racial
396 differences in exposure and risk. Non-whites only account for 18.7% of the SHOW sample,
397 compared with approximately 35% in each NHANES sample. While the SHOW study
398 oversampled non-whites in 2019, they did not conduct oversampling of non-whites during their
399 statewide sampling years (2014-2016) used in this study. Due to Wisconsin's proportionately
400 small non-white population, the non-white sample in the SHOW study sample is small. This
401 likely resulted in little variability within the non-white subpopulation which may have resulted in
402 an unrepresentative substratum of non-whites in the state. As such, those who were included are
403 weighted to represent a larger proportion of their racial/ethnic subpopulation. Racial and ethnic
404 minorities, and those of lower socio-economic and education attainment, are more likely to
405 reside near industrial and contamination sites that are at greater risk of exposure to
406 environmental contaminants of concern, such as PFAS. This was seen in biomonitoring of a
407 high-risk community due to manufacturing in Alabama where PFOS levels were ~2 times higher
408 in African Americans compared to whites in the study [26]. We would expect a similar trend in
409 SHOW, but additional testing or sampling is needed.

410
411 The SHOW's relatively small substratum of non-whites was a limitation of the study. This may
412 have resulted in a less balanced comparison to NHANES and limited the study's ability to
413 identify racial disparities relating to PFAS that may exist in Wisconsin. While race may be an
414 important predictor of PFAS exposure, there are other demographic differences between SHOW
415 and NHANES that may have contributed to differences in the comparison of results. On average,
416 SHOW participants had a slightly higher education level and income to poverty ratio than
417 NHANES participants in all sampling years. It is well-known that lower income status is
418 associated with increased adverse environmental exposures [50], which may have contributed to

419 the lower levels of PFAS in SHOW participants than may exist in the state's population. There is
420 evidence that higher PFAS exposure is associated with lower educational attainment [46].

421
422 While the SHOW 2014-2016 sample is representative of the state, its primary sampling unit was
423 at the county level, and only 9 counties were represented. Selection criteria used for SHOW's
424 sampling frame to ensure representation was based on socioeconomic status and population
425 density; geographical representation was not a factor. This is a significant limitation of the study
426 as northern regions of the state, and more isolated areas, are not represented. Future PFAS
427 biomonitoring in the state should include oversampling of non-whites and geographical
428 representation to adequately capture varied land use throughout the state; ensuring unique areas
429 in central sands regions and northeast areas with karst geology are included, due to potentially
430 vulnerable groundwater contamination. Additionally, data on education and smoking status were
431 unavailable for 18- and 19-year-olds for NHANES, so some demographic comparisons do not
432 include these individuals. Lastly, this study was cross-sectional, with serum concentrations from
433 over 6 years ago. Hence, not only can causality not be inferred, but changes over time are not
434 captured, and current PFAS concentrations among the state's population today may be different
435 than seen in this study. Future PFAS biomonitoring in Wisconsin should consider repeat testing,
436 especially as short chain PFAS become more widely used and long chain PFAS are phased out.

437
438 While this study has several limitations, it has many strengths. This is the first statewide
439 representative cohort for which we have baseline PFAS serum concentrations. Studies-to-date
440 have conducted biomonitoring on specific cohorts (i.e. California Teachers Study), among high-
441 risk occupational workers (Firefighters), or communities residing near a contamination site.
442 While Yu et al. conducted statewide biomonitoring, they relied convenience testing from clinical
443 and lab sera [44], whereas SHOW relied on probability sampling to produce a statewide
444 representative sample with weights. This study also tested a wider range of PFAS compounds
445 with LLOD for many. This was an important contribution to the field and increased our
446 understanding of the extent other PFAS compounds are in the environment and in our bodies.

447
448 These data suggest that Wisconsin residents may not be disproportionately burdened by PFAS
449 contamination compared to the wider US population. More research is needed to determine the
450 extent of PFAS exposure in Wisconsin which ensures geographical variation and adequate
451 oversampling of non-whites. This is the beginning of our understanding of PFAS exposure
452 among Wisconsin residents, but importantly, it offers a baseline prevalence of PFAS. Future
453 directions include utilizing the rich SHOW survey data to better characterize PFAS serum levels
454 based on diet, housing, and other factors. These findings can help state agencies in resource
455 allocation for additional PFAS biomonitoring, and direct resources where most needed.
456 Additionally, residential address and residential history is known for SHOW participants, which
457 increases the capacity to study cumulative exposure to PFAS through neighborhood-level
458 contextual factors like industrial sites and nearby land uses through the adult life course. Finally,
459 longitudinal follow-up should be conducted in the future to track changes in PFAS burden in the
460 population over time.

461
462 **Data Availability Statement**

463 The datasets generated during and analyzed during the current study are not publicly available
464 due to HIPAA protections for SHOW participants but may be available from the corresponding
465 author on reasonable request with IRB approval.

466

467 **Acknowledgements**

468 The authors would like to thank all the SHOW investigators who made this work possible,
469 WSLH staff who contributed to the creation of this data, and the SHOW participants.

470

471 **Author Contributions**

472 Conceptualization: A.S., N.S., K.M.; Methodology: N.S., M.L., A.S., Sample Analysis: N.S.,
473 M.L., Data Analysis: A.S., R.P.; Draft Preparation: A.S., R.P., N.S., K.M.; Review and Editing:
474 A.S., R.P., R.I., J.M., K.M.; Supervision: K.M., N.S.; Funding Acquisition: A.S., N.S.

475

476 **Funding**

477 Funding for SHOW comes from the Wisconsin Division of Public Health, the Wisconsin
478 Partnership Program (PERC) Award (223 PRJ 25DJ), the National Institutes of Health's Clinical
479 and Translational Science Award (5UL 1RR025011), and the National Heart Lung and Blood
480 Institute (1 RC2 HL101468) and a core grant to the Center for Demography and Ecology at the
481 University of Wisconsin-Madison (P2C HD047873).

482

483 **Ethical Approval**

484 The SHOW protocol and informed consent documents are approved by the Health Sciences
485 Institutional Review Board of the University of Wisconsin-Madison. Participants in SHOW
486 gave consent to their information being used for research prior to this study.

487

488 **Competing Interests**

489 The authors declare no competing interests related to this work.

490

491 **Tables and Figures**

492

Table 1.

Demographics characteristics of SHOW 2014-2016 compared with NHANES 2015-2016, and NHANES 2017-2018 cohorts.

| | SHOW 2014-2016 (n =605) | | | NHANES 2015-2016 (n= 1829) | | | NHANES 2017-2018 (n=1862) | | |
|---|----------------------------|-----------------------|------------|--------------------------------|-----------------------|------------|-------------------------------|-----------------------|-----------|
| | n | Column % ^a | 95% CI (%) | n | Column % ^b | 95% CI (%) | n | Column % ^b | 95% CI |
| Gender | | | | | | | | | |
| Male | 257 | 49.3 | 44.8,53.8 | 865 | 48.4 | 45.1,51.6 | 922 | 48.5 | 45.1,52.0 |
| Female | 346 | 50.7 | 46.2,55.2 | 964 | 51.6 | 48.4,54.9 | 940 | 51.5 | 48.0,54.9 |
| Age (in years) | | | | | | | | | |
| 18-39 | 162 | 36.0 | 31.5,40.6 | 674 | 37.6 | 34.6,40.7 | 641 | 38.5 | 35.2,41.8 |
| 40-59 | 208 | 36.4 | 32.1,40.7 | 581 | 35.1 | 31.8,38.3 | 558 | 33.4 | 29.9,36.9 |
| 60-94 | 233 | 27.6 | 24.1,31.2 | 574 | 27.3 | 24.4,30.2 | 663 | 28.1 | 25.1,31.0 |
| Race | | | | | | | | | |
| White (non-Hispanic) | 502 | 81.3 | 77.5,85.0 | 563 | 62.9 | 60.2,65.7 | 644 | 62.3 | 59.4,65.3 |
| Non-white | 100 | 18.7 | 15.0,22.5 | 1266 | 37.1 | 34.3,39.8 | 1218 | 37.7 | 34.7,40.6 |
| Education* | | | | | | | | | |
| H.S./GED or less | 151 | 27.1 | 23.0,30.5 | 778 | 34.2 | 31.3,37.2 | 771 | 38.2 | 34.9,41.6 |
| Some college | 217 | 36.1 | 31.8,40.4 | 547 | 34.8 | 31.6,37.9 | 574 | 30.1 | 27.0,33.1 |
| Bachelors or higher | 235 | 36.8 | 32.6,41.1 | 424 | 31.0 | 27.8,34.2 | 415 | 31.7 | 28.1,35.3 |
| Income/Poverty Ratio^c | | | | | | | | | |
| <1 | 44 | 14.0 | 10.7,17.3 | 395 | 21.0 | 18.7,23.2 | 351 | 22.6 | 20.1,25.2 |
| 1-3 | 220 | 38.9 | 34.5,43.3 | 708 | 33.2 | 30.3,36.1 | 717 | 31.7 | 28.8,34.6 |
| >3 | 311 | 47.1 | 42.6,51.5 | 445 | 45.9 | 42.5,49.2 | 422 | 45.7 | 42.1,49.2 |
| Smoking Status* | | | | | | | | | |
| Current | 73 | 15.0 | 11.5,18.6 | 356 | 19.6 | 17.1,22.1 | 334 | 17.3 | 14.8,19.8 |
| Former | 146 | 23.7 | 19.9,27.6 | 389 | 23.8 | 21.0,26.7 | 408 | 21.3 | 18.4,24.1 |
| Never | 345 | 61.2 | 56.7,65.6 | 1081 | 56.6 | 53.3,59.8 | 1120 | 61.4 | 58.1,64.8 |
| BMI | | | | | | | | | |
| < 25 | 161 | 26.6 | 22.7,30.5 | 537 | 31.3 | 28.3,34.3 | 541 | 29.0 | 25.8,32.1 |
| 25-30 | 200 | 31.4 | 27.3,35.4 | 548 | 29.4 | 26.4,32.3 | 577 | 31.5 | 28.2,34.8 |
| > 30 | 237 | 42.1 | 37.6,46.5 | 744 | 39.3 | 36.2,42.5 | 744 | 39.5 | 36.2,42.9 |

^a SHOW sample weights used for statewide representation; ^b NHANES sample weights used for national representation; ^c Income/Poverty Ratio is calculated by dividing total family income by the poverty guidelines from the Department of Health and Human Services (HHS) for the number of people supported by that income. *18 and 19 year olds excluded from education and smoking data in NHANES sample Abbreviations: Met Min / wk - Metabolic minutes per week; H.S. – High School; G.E.D – General Education Diploma; BMI – Body Mass Index

493 Table 2. Summary of SHOW results for all PFAS analytes

IOW serum PFAS result summary

Number of samples = 605

| Analyte | Abbreviation | CAS-RNb | Detection Limit | # positive SHOW results | % positive results | Weighted Geometric Mean | Min result | Max Result |
|--|--------------|-------------|-----------------|-------------------------|--------------------|-------------------------|------------|------------|
| perfluoro-n-butananesulfonic acid | PFBS | 375-73-5 | 0.022 | 78 | 12.8926 | 0.0708 | 0.022 | 0.158 |
| perfluoropentanesulfonic acid | PFPeS | 2706-91-4 | 0.015 | 351 | 58.0165 | 0.074 | 0.015 | 0.523 |
| perfluoro-n-hexanesulfonic acid | PFHxS | 355-46-4 | 0.028 | 599 | 99.0083 | 1.138 | 0.033 | 30 |
| perfluoro-n-heptanesulfonic acid | PFHpS | 375-92-8 | 0.027 | 583 | 96.3636 | 0.168 | 0.027 | 2.58 |
| perfluoro-n-octanesulfonic acid | PFOS | 1763-23-1 | 0.036 | 602 | 99.5041 | 4.513 | 0.056 | 32.9 |
| perfluorononanesulfonic acid | PFNS | 68259-12-1 | 0.018 | 1 | 0.16529 | 0.071 | 0.021 | 0.021 |
| perfluoro-n-decanesulfonic acid | PFDS | 335-77-3 | 0.049 | 16 | 2.64463 | 0.071 | 0.05 | 0.188 |
| perfluorooctanesulfonamide | FOSA | 754-91-6 | 0.029 | 1 | 0.16529 | 0.071 | 0.055 | 0.055 |
| methylperfluorooctanesulfonamide | NMeFOSA | 31506-32-8 | 0.246 | 0 | 0 | N/A | N/A | N/A |
| ethylperfluorooctanesulfonamide | NEtFOSA | 4151-50-2 | 0.064 | 3 | 0.5 | 0.071 | 0.085 | 0.102 |
| methylperfluorooctanesulfonamide | NMeFOSAA | 2355-31-9 | 0.145 | 294 | 48.6 | 0.137 | 0.147 | 2.8 |
| ethylperfluorooctanesulfonamide | NEtFOSAA | 2991-50-6 | 0.184 | 13 | 2.15 | 0.073 | 0.195 | 2.02 |
| Methylperfluorooctanesulfonamide | N-MeFOSE | 24448-09-7 | 0.099 | 1 | 0.17 | 0.071 | 0.128 | 0.128 |
| Ethylperfluorooctanesulfonamide | N-EtFOSE | 1691-99-2 | 0.139 | 0 | 0 | N/A | N/A | N/A |
| 2 Fluorotelomer sulfonic acid | 4:2 FTSA | 757124-72-4 | 0.067 | 50 | 8.26 | 0.072 | 0.066 | 0.151 |
| 2 Fluorotelomer sulfonic acid | 6:2 FTSA | 27619-97-2 | 0.149 | 0 | 0 | N/A | N/A | N/A |
| 2 Fluorotelomer sulfonic acid | 8:2 FTSA | 39108-34-4 | 0.101 | 26 | 4.3 | 0.072 | 0.102 | 0.227 |
| 2 Fluorotelomer sulfonic acid | 10:2 FTSA | 120226-60-0 | 0.081 | 33 | 5.45 | 0.071 | 0.082 | 0.122 |
| Chlorohexadecafluoro-3-oxanonane-1-sulfonic acid | 9Cl-PF3ONS | 756426-58-1 | 0.009 | 252 | 41.65 | 0.071 | 0.009 | 0.293 |
| perfluoro-n-butanoic acid | PFBA | 375-22-4 | 0.039 | 173 | 28.6 | 0.074 | 0.039 | 0.546 |
| perfluoro-n-pentanoic acid | PFPeA | 2706-90-3 | 0.015 | 39 | 6.45 | 0.072 | 0.016 | 1.11 |

| | | | | | | | | |
|---|--------------|-------------|-------|-----|-------|-------|-------|-------|
| perfluoro-n-hexanoic acid | PFHxA | 307-24-4 | 0.043 | 2 | 0.33 | 0.071 | 0.046 | 0.071 |
| perfluoro-n-heptanoic acid | PFHpA | 375-85-9 | 0.031 | 352 | 58.18 | 0.075 | 0.031 | 2.85 |
| perfluoro-n-octanoic acid | PFOA | 335-67-1 | 0.025 | 603 | 99.67 | 1.196 | 0.038 | 19.1 |
| perfluoro-n-nonanoic acid | PFNA | 375-95-1 | 0.021 | 601 | 99.34 | 0.452 | 0.022 | 12 |
| perfluoro-n-decanoic acid | PFDA | 335-76-2 | 0.024 | 598 | 98.84 | 0.142 | 0.024 | 4.51 |
| perfluoro-n-undecanoic acid | PFUnDA | 2058-94-8 | 0.042 | 460 | 76.03 | 0.094 | 0.042 | 1.36 |
| perfluoro-n-dodecanoic acid | PFDoA | 307-55-1 | 0.053 | 23 | 3.8 | 0.071 | 0.057 | 0.295 |
| perfluoro-n-tridecanoic acid | PFTriA | 72629-94-8 | 0.391 | 0 | 0 | N/A | N/A | N/A |
| perfluoro-n-tetradecanoic acid | PFTeA | 376-06-7 | 0.032 | 2 | 0.33 | 0.071 | 0.035 | 0.041 |
| perfluoro-n-hexadecanoic acid | PFHxDA | 67905-19-5 | 0.085 | 1 | 0.17 | 0.071 | 0.097 | 0.097 |
| perfluoro-n-octadecanoic acid | PFODA | 16517-11-6 | 0.164 | 0 | 0 | N/A | N/A | N/A |
| 8-Dioxa-3H-perfluorononanoic acid | DONA | 919005-14-4 | 0.012 | 0 | 0 | N/A | N/A | N/A |
| 1,1-dichloro-2,2-bis(4-chloro-3-methylphenyl)ethane-1,1-dithiolane-2-thione | 11Cl-PF3OUdS | 763051-92-9 | 0.011 | 2 | 0.33 | 0.071 | 0.13 | 0.14 |
| 2,2-bis(4-chlorophenyl)propane-1,1-dithiolane-2-thione | 6:2 diPAP | 57677-95-9 | 0.077 | 23 | 3.8 | 0.073 | 0.078 | 0.451 |
| 2,2-bis(4-chlorophenyl)propane-1,1-dithiolane-2-thione | 8:2 diPAP | 678-41-1 | 0.134 | 3 | 0.5 | 0.071 | 0.254 | 0.296 |
| perfluoro-2-methoxypropanoic acid | PFMPA | 377-73-1 | 0.019 | 0 | 0 | N/A | N/A | N/A |
| perfluoro-2-methoxybutanoic acid | PFMBA | 863090-89-5 | 0.017 | 0 | 0 | N/A | N/A | N/A |

Highlighted rows indicate inclusion in both SHOW and NHANES analyses. Compounds with percentages of positive results less than 15% in SHOW were not included in comparisons as we are unable to draw reliable conclusions

494

Table 3. Geometric Means and Percentile Comparisons between SHOW and NHANES

| | | n | Geometric mean (95% CI) | 50th (95% CI) | 75th (95% CI) | 90th (95% CI) | 95th (95% CI) | p-trend |
|------|--------|------|-------------------------|--------------------|--------------------|-----------------------|----------------------|---------|
| PFOS | SHOW | 605 | 4.51 (4.18 - 4.87) | 5.01 (4.54 - 5.49) | 8.19 (7.53 - 8.85) | 11.28 (10.61 - 12.43) | 14.97(13.32 - 16.77) | 0.54 |
| | NHANES | 1829 | 4.97 (4.71 - 5.25) | 5.20 (4.80- 5.40) | 8.60 (8.00- 9.40) | 13.80 (12.90- 15.40) | 19.00 (16.80- 21.50) | |
| PFOA | SHOW | 605 | 1.20 (1.12 - 1.27) | 1.30 (1.20 - 1.40) | 1.90 (1.80 - 1.90) | 2.60 (2.40 - 2.90) | 3.30 (2.90 - 3.50) | <0.0001 |

| | | | | | | | | |
|-------|--------|------|--------------------|--------------------|--------------------|--------------------|--------------------|---------|
| | NHANES | 1829 | 1.59 (1.52 - 1.67) | 1.60 (1.50-1.70) | 2.50 (2.20-2.50) | 3.40 (3.20-3.60) | 4.20 (3.80-4.70) | |
| PFNA | SHOW | 605 | 0.45 (0.43-0.48) | 0.50 (0.40 - 0.50) | 0.70 (0.60 - 0.70) | 1.00 (0.90 - 1.20) | 1.40 (1.20 - 1.70) | <0.0001 |
| | NHANES | 1829 | 0.59 (0.56-0.62) | 0.50 (0.40-0.50) | 0.90 (0.80-0.90) | 1.40 (1.20-1.40) | 1.90 (1.50-2.10) | |
| PFHxS | SHOW | 605 | 1.14 (1.04-1.24) | 1.30 (1.20 - 1.40) | 2.10 (1.80 - 2.30) | 3.30 (3.00 - 4.00) | 4.60 (4.00 - 5.60) | 0.58 |
| | NHANES | 1829 | 1.22 (1.15-1.29) | 1.20 (1.10-1.30) | 2.10 (1.90-2.20) | 3.40 (3.20-3.80) | 5.00 (4.10-5.80) | |
| PFDA | SHOW | 605 | 0.14 (0.13-0.15) | 0.10 (0.10 - 0.20) | 0.20 (0.20-0.20) | 0.30 (0.30-0.40) | 0.50 (0.40-0.60) | 0.023 |
| | NHANES | 1829 | 0.16 (0.15-0.17) | 0.10 (0.10-0.10) | 0.20 (0.20-0.20) | 0.40 (0.30-0.40) | 0.70 (0.50-0.70) | |
| PFHPS | SHOW | 605 | 0.17 (0.16-0.18) | 0.17 (0.16-0.19) | 0.28 (0.26-0.30) | 0.37 (0.35-0.40) | 0.46 (0.42-0.49) | <0.0001 |
| | NHANES | 2133 | 0.23 (0.22-0.25) | 0.19 (0.090-0.19) | 0.34 (0.28-0.34) | 0.60 (0.50-0.60) | 0.95 (0.69-1.40) | |

495

Table 4. Geometric means and percentiles of serum PFOS by demographic characteristics- comparing 18+ in SHOW 2014-2016 with U.S. NHANES 2015-2016

| PFOS | | n | Geometric mean (95% CI) | 50th (95% CI) | 75th (95% CI) | 90th (95% CI) | 95th (95% CI) |
|------|--------|-------|-------------------------|------------------|------------------|------------------|-------------------|
| Age | | | | | | | |
| SHOW | 18-39 | 162 | 3.13 (2.71-3.62) | 3.70 (3.30-4.10) | 5.50 (4.60-6.20) | 7.60 (6.30-8.80) | 8.80 (7.70-10.20) |
| | NHANES | 18-39 | 674 | 3.49 (3.20-3.79) | 3.60 (3.20-3.80) | 5.90 (5.30-6.50) | 9.50 (8.20-10.60) |

| | | | | | | | |
|--------|-----------------------------|------|--------------------------|-------------------------|----------------------------|----------------------------|----------------------------|
| | | | 4.46 (3.97- 5.00) | 4.90 (4.20- 5.50) | 8.20 (7.00- 9.10) | 10.80 (9.60- 12.30) | 12.60 (11.10- 16.50) |
| SHOW | 40-59 | 208 | | | | | |
| | | | 5.20 (4.77- 5.66) | 5.30 (4.60- 5.70) | 8.20 (7.10- 9.70) | 13.60 (11.40- 16.00) | 17.40 (15.70- 22.60) |
| NHANES | 40-59 | 581 | | | | | |
| | | | 7.39 (6.72- 8.312) | 7.80 (7.20- 8.70) | 11.20 (10.40- 12.80) | 16.60 (14.10- 18.70) | 19.70 (17.20- 25.30) |
| SHOW | 60+ | 233 | | | | | |
| | | | 7.56 (6.83- 8.37) | 7.90 (7.10- 8.50) | 12.70 (11.10- 13.60) | 19.10 (16.70- 22.10) | 26.30 (21.80- 30.50) |
| NHANES | 60+ | 574 | | | | | |
| Sex | | | | | | | |
| | | | 5.08 (4.49- 5.74) | 5.70 (5.20- 6.40) | 8.90 (8.20- 9.30) | 12.20 (10.70- 14.30) | 16.40 (13.60- 18.50) |
| SHOW | Male | 257 | | | | | |
| | | | 6.59 (6.16- 7.05) | 6.60 (6.00- 7.10) | 10.40 (9.60- 11.10) | 16.10 (14.10- 18.90) | 22.00 (19.00- 24.50) |
| NHANES | Male | 865 | | | | | |
| | | | 4.02 (3.67- 4.41) | 4.10 (3.70- 4.60) | 7.20 (6.40- 8.00) | 10.90 (9.70- 12.20) | 13.60 (11.60- 16.40) |
| SHOW | Female | 346 | | | | | |
| | | | 3.81 (3.53- 4.12) | 3.80 (3.40- 4.10) | 6.50 (5.90- 7.20) | 11.10 (10.20- 12.60) | 15.80 (13.20- 17.80) |
| NHANES | Female | 964 | | | | | |
| Race | | | | | | | |
| | | | 4.91 (4.54- 5.31) | 5.45 (4.92- 5.87) | 8.50 (7.82- 9.10) | 12.14 (11.02- 13.46) | 15.59 (13.49- 16.81) |
| SHOW | White (Non- Hispanic) | 502 | | | | | |
| | | | 5.16 (4.77- 5.58) | 5.30 (4.74- 5.62) | 9.03 (7.90- 10.17) | 13.41 (12.30- 15.88) | 17.64 (15.97- 21.94) |
| NHANES | White (Non- Hispanic) | 563 | | | | | |
| | | | 3.16 (2.55- 3.91) | 3.57 (2.93- 4.19) | 5.75 (4.43- 8.03) | 9.25 (7.66- 11.06) | 10.48 (8.75- 18.06) |
| SHOW | Non- White | 100 | | | | | |
| | | | 4.65 (4.38- 4.95) | 4.73 (4.40- 5.10) | 8.34 (7.74- 8.85) | 14.51 (12.99- 15.99) | 21.79 (18.29- 23.54) |
| NHANES | Non- White | 1266 | | | | | |

Table 5. Geometric means and percentiles of serum PFOA by demographic characteristics- comparing 18+ in SHOW 2014-2016 with U.S. NHANES 2015-2016

| PFOA | | n | Geometric mean (95% CI) | 50th (95% CI) | 75th (95% CI) | 90th (95% CI) | 95th (95% CI) |
|--------|----------------------|-----|-------------------------|------------------|------------------|------------------|-------------------|
| Age | | | | | | | |
| SHOW | 18-39 | 162 | 0.93 (0.82-1.05) | 1.10 (0.90-1.20) | 1.60 (1.40-1.80) | 2.00 (1.90-2.30) | 2.40 (2.00-3.20) |
| NHANES | 18-39 | 674 | 1.31 (1.21-1.40) | 1.40 (1.20-1.40) | 2.00 (1.80-2.20) | 2.80 (2.50-3.00) | 3.50 (2.90-3.90) |
| SHOW | 40-59 | 208 | 1.28 (1.16-1.41) | 1.30 (1.20-1.50) | 1.80 (1.70-2.10) | 2.60 (2.40-3.10) | 3.30 (2.70-4.60) |
| NHANES | 40-59 | 581 | 1.64 (1.53-1.77) | 1.60 (1.40-1.80) | 2.40 (2.10-2.50) | 3.30 (3.10-3.60) | 3.90 (3.50-5.20) |
| SHOW | 60+ | 233 | 1.51 (1.38-1.65) | 1.50 (1.40-1.80) | 2.30 (2.10-2.50) | 3.30 (2.80-3.50) | 3.50 (3.40-4.20) |
| NHANES | 60+ | 574 | 2.01 (1.81-2.22) | 2.10 (1.90-2.20) | 2.80 (2.60-3.10) | 4.20 (3.60-4.90) | 5.20 (4.60-6.90) |
| Sex | | | | | | | |
| SHOW | Male | 257 | 1.25 (1.13-1.37) | 1.40 (1.30-1.50) | 1.90 (1.80-2.00) | 2.60 (2.40-3.00) | 3.20 (2.90-3.60) |
| NHANES | Male | 865 | 1.85 (1.75-1.96) | 1.90 (1.70-2.00) | 2.60 (2.50-2.70) | 3.40 (3.20-3.60) | 4.10 (3.60-5.010) |
| SHOW | Female | 346 | 1.15 (1.06-1.25) | 1.20 (1.10-1.20) | 1.80 (1.70-2.00) | 2.70 (2.40-3.10) | 3.50 (2.90-4.20) |
| NHANES | Female | 964 | 1.39 (1.29-1.49) | 1.40 (1.30-1.50) | 2.30 (2.00-2.40) | 3.40 (2.90-3.90) | 4.30 (3.90-6.10) |
| Race | | | | | | | |
| SHOW | White (Non-Hispanic) | 502 | 1.28 (1.20-1.37) | 1.40 (1.30-1.50) | 1.90 (1.80-2.00) | 2.80 (2.50-3.10) | 3.40 (3.10-4.00) |

497

| | | | | | | | |
|--------|----------------------|------|------------------|------------------|------------------|------------------|------------------|
| NHANES | White (Non-Hispanic) | 563 | 1.72 (1.60-1.84) | 1.80 (1.60-1.90) | 2.60 (2.40-2.70) | 3.50 (3.20-3.80) | 4.60 (3.90-5.60) |
| SHOW | Non-White | 100 | 0.90 (0.77-1.05) | 1.00 (0.80-1.10) | 1.40 (1.20-1.80) | 2.00 (1.60-2.50) | 2.40 (2.00-3.00) |
| NHANES | Non-White | 1266 | 1.40 (1.34-1.47) | 1.40 (1.30-1.40) | 2.10 (2.00-2.20) | 3.10 (2.80-3.30) | 4.00 (3.60-4.10) |

Table 6. Geometric means and percentiles of serum PFNA by demographic characteristics- comparing 18+ in SHOW 2014-2016 with U.S. NHANES 2015-2016

| PFNA | | n | Geometric mean (95% CI) | 50th (95% CI) | 75th (95% CI) | 90th (95% CI) | 95th (95% CI) |
|--------|-------|-----|-------------------------|------------------|------------------|------------------|------------------|
| Age | | | | | | | |
| SHOW | 18-39 | 162 | 0.36 (0.32-0.41) | 0.40 (0.30-0.40) | 0.60 (0.50-0.70) | 0.80 (0.70-1.10) | 1.10 (0.80-1.40) |
| NHANES | 18-39 | 674 | 0.46 (0.43-0.50) | 0.40 (0.30-0.40) | 0.70 (0.60-0.70) | 1.00 (0.90-1.00) | 1.30 (1.10-1.50) |
| SHOW | 40-59 | 208 | 0.44 (0.40-0.48) | 0.40 (0.40-0.50) | 0.60 (0.60-0.70) | 0.90 (0.80-1.20) | 1.30 (1.00-1.70) |
| NHANES | 40-59 | 581 | 0.60 (0.55-0.66) | 0.50 (0.50-0.60) | 0.90 (0.80-1.00) | 1.30 (1.20-1.50) | 1.90 (1.40-2.30) |
| SHOW | 60+ | 233 | 0.62 (0.56-0.67) | 0.60 (0.60-0.70) | 0.90 (0.80-0.90) | 1.40 (1.20-1.80) | 2.10 (1.50-2.60) |
| NHANES | 60+ | 574 | 0.78 (0.71-0.85) | 0.70 (0.60-0.80) | 1.10 (1.00-1.30) | 1.70 (1.50-2.00) | 2.30 (1.90-2.60) |
| Sex | | | | | | | |
| SHOW | Male | 257 | 0.47 (0.43-0.51) | 0.50 (0.40-0.50) | 0.70 (0.60-0.80) | 1.00 (0.90-1.20) | 1.40 (1.10-2.10) |
| NHANES | Male | 865 | 0.64 (0.60-0.69) | 0.50 (0.40-0.50) | 0.90 (0.80-1.00) | 1.40 (1.10-1.40) | 1.90 (1.50-2.10) |

| | | | | | | | |
|--------|----------------------|------|------------------|------------------|------------------|------------------|------------------|
| SHOW | Female | 346 | 0.44 (0.40-0.48) | 0.40 (0.40-0.50) | 0.70 (0.60-0.80) | 1.10 (0.90-1.30) | 1.40 (1.20-2.00) |
| NHANES | Female | 964 | 0.54 (0.50-0.58) | 0.40 (0.30-0.40) | 0.80 (0.70-0.80) | 1.30 (1.10-1.40) | 1.90 (1.40-2.40) |
| Race | | | | | | | |
| SHOW | White (Non-Hispanic) | 502 | 0.48 (0.45-0.51) | 0.50 (0.40-0.50) | 0.70 (0.70-0.80) | 1.10 (0.90-1.30) | 1.50 (1.30-2.10) |
| NHANES | White (Non-Hispanic) | 563 | 0.58 (0.54-0.62) | 0.50 (0.40-0.50) | 0.90 (0.70-0.90) | 1.30 (1.10-1.40) | 1.90 (1.40-2.30) |
| SHOW | Non-White | 100 | 0.36 (0.31-0.41) | 0.30 (0.30-0.40) | 0.60 (0.50-0.70) | 0.80 (0.60-1.10) | 1.00 (0.80-1.50) |
| NHANES | Non-White | 1266 | 0.60 (0.57-0.63) | 0.50 (0.40-0.50) | 0.90 (0.80-1.00) | 1.40 (1.30-1.50) | 1.90 (1.60-2.00) |

498

499

500
501

Bibliography

- 502 1 Ghisi R, Vamerali T, Manzetti S. Accumulation of perfluorinated alkyl substances (PFAS) in
503 agricultural plants: A Review. *Environmental Research*. 2019;169:326–41.
- 504 2 Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the
505 pathways of human exposure to poly- and perfluoroalkyl substances (pfass) and present
506 understanding of health effects. *Journal of Exposure Science & Environmental
507 Epidemiology*. 2018;29(2):131–47.
- 508 3 Haukås M, Berger U, Hop H, Gulliksen B, Gabrielsen GW. Bioaccumulation of per- and
509 polyfluorinated alkyl substances (PFAS) in selected species from the Barents Sea Food
510 web. *Environmental Pollution*. 2007;148(1):360–71.
- 511 4 Faithfull NS, Weers JG. Perfluorocarbon compounds. *Vox Sanguinis*. 1998;74(S2):243–8.
- 512 5 Hu XC, Andrews DQ, Lindstrom AB, Bruton TA, Schaidler LA, Grandjean P, et al. Detection
513 of poly- and perfluoroalkyl substances (pfass) in U.S. drinking water linked to industrial
514 sites, military fire training areas, and wastewater treatment plants. *Environmental Science
515 & Technology Letters*. 2016;3(10):344–50.
- 516 6 Kurwadkar S, Dane J, Kanel SR, Nadagouda MN, Cawdrey RW, Ambade B, et al. Per- and
517 polyfluoroalkyl substances in water and wastewater: A critical review of their global
518 occurrence and distribution. *Science of The Total Environment*. 2022;809:151003.
- 519 7 Sinclair GM, Long SM, Jones OAH. What are the effects of PFAS exposure at
520 environmentally relevant concentrations? *Chemosphere*. 2020;258:127340.
- 521 8 Per- and polyfluorinated substances (PFAS) factsheet [Internet]. Centers for Disease Control
522 and Prevention. Centers for Disease Control and Prevention; 2022 [cited 2023Jan17].
523 Available from: https://www.cdc.gov/biomonitoring/PFAS_FactSheet.html
- 524 9 Fenton SE, Ducatman A, Boobis A, DeWitt JC, Lau C, Ng C, et al. Per□ and polyfluoroalkyl
525 substance toxicity and human health review: Current state of knowledge and strategies for
526 informing future research. *Environmental Toxicology and Chemistry*. 2020;40(3):606–30.
- 527 10 DeWitt JC. *Toxicological effects of perfluoroalkyl and polyfluoroalkyl substances*. Cham,
528 New York: Springer International Publishing; 2015.
- 529 11 Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol,
530 body weight, and insulin resistance in the general U.S. population. *Environmental Health
531 Perspectives*. 2010;118(2):197–202.

- 532 12 Bassler J, Ducatman A, Elliott M, Wen S, Wahlang B, Barnett J, et al. Environmental
533 perfluoroalkyl acid exposures are associated with liver disease characterized by apoptosis
534 and altered serum adipocytokines. *Environmental Pollution*. 2019;247:1055–63.
- 535 13 Wikström S, Lin P-I, Lindh CH, Shu H, Bornehag C-G. Maternal serum levels of
536 perfluoroalkyl substances in early pregnancy and offspring birth weight. *Pediatric*
537 *Research*. 2019;87(6):1093–9.
- 538 14 von Holst H, Nayak P, Dembek Z, Buehler S, Echeverria D, Fallacara D, et al. Perfluoroalkyl
539 Substances Exposure and immunity, allergic response, infection, and asthma in children:
540 Review of Epidemiologic Studies. *Heliyon*. 2021;7(10).
- 541 15 Borghese MM, Walker M, Helewa ME, Fraser WD, Arbuckle TE. Association of
542 perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC
543 study. *Environment International*. 2020;141:105789.
- 544 16 Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, et al. Pre-natal
545 exposure to perfluoroalkyl substances may be associated with altered vaccine antibody
546 levels and immune-related health outcomes in early childhood. *Journal of*
547 *Immunotoxicology*. 2013;10(4):373–9.
- 548 17 Brennan NM, Evans AT, Fritz MK, Peak SA, von Holst HE. Trends in the regulation of per-
549 and polyfluoroalkyl substances (PFAS): A scoping review. *International Journal of*
550 *Environmental Research and Public Health*. 2021;18(20):10900.
- 551 18 Chen J, Tang L, Chen W-Q, Peaslee GF, Jiang D. Flows, stock, and emissions of poly- and
552 perfluoroalkyl substances in California carpet in 2000–2030 under different scenarios.
553 *Environmental Science & Technology*. 2020;54(11):6908–18.
- 554 19 Podder A, Sadmani AHMA, Reinhart D, Chang N-B, Goel R. Per and poly-fluoroalkyl
555 substances (PFAS) as a contaminant of emerging concern in Surface Water: A
556 transboundary review of their occurrences and toxicity effects. *Journal of Hazardous*
557 *Materials*. 2021;419:126361.
- 558 20 US EPA. Lifetime Drinking Water Health Advisories for Four Perfluoroalkyl Substances.
559 2022; 87 FRL 9855–01–OW. (To be codified and 87 C.F.R. pts. 36848, 36849).
- 560 21 Kidd J, Fabricatore E, Jackson D. Current and future federal and state sampling guidance for
561 per- and polyfluoroalkyl substances in environmental matrices. *Science of The Total*
562 *Environment*. 2022;836:155523.
- 563 22 Birnbaum LS, Grandjean P. Alternatives to pfas: Perspectives on the science. *Environmental*
564 *Health Perspectives*. 2015;123(5).

- 565 23 Aylward LL, Seiber JN, Hays SM. California biomonitoring data: Comparison to NHANES
566 and interpretation in a risk assessment context. *Regulatory Toxicology and Pharmacology*.
567 2015;73(3):875–84.
- 568 24 Graber JM, Alexander C, Laumbach RJ, Black K, Strickland PO, Georgopoulos PG, et al. Per
569 and polyfluoroalkyl substances (PFAS) blood levels after contamination of a community
570 water supply and comparison with 2013–2014 NHANES. *Journal of Exposure Science &*
571 *Environmental Epidemiology*. 2018;29(2):172–82.
- 572 25 Graber JM, Black TM, Shah NN, Caban-Martinez AJ, Lu S-en, Brancard T, et al. Prevalence
573 and predictors of per- and polyfluoroalkyl substances (PFAS) serum levels among
574 members of a suburban US volunteer fire department. *International Journal of*
575 *Environmental Research and Public Health*. 2021;18(7):3730.
- 576 26 Petriello MC, Mottaleb MA, Serio TC, Balyan B, Cave MC, Pavuk M, et al. Serum
577 concentrations of legacy and emerging per- and polyfluoroalkyl substances in the Anniston
578 Community Health Surveys (ACHS I and ACHS II). *Environment International*.
579 2022;158:106907.
- 580 27 Yu CH, Weisel CP, Alimokhtari S, Georgopoulos PG, Fan Z(T. Biomonitoring: A tool to
581 assess PFNA body burdens and evaluate the effectiveness of drinking water intervention
582 for communities in New Jersey. *International Journal of Hygiene and Environmental*
583 *Health*. 2021;235:113757.
- 584 28 Multiple state agencies responding to PFAS contamination on French Island [Internet].
585 Wisconsin Department of Natural Resources. Wisconsin Department of Natural Resources;
586 2021 [cited 2023Jan17]. Available from:
587 <https://dnr.wisconsin.gov/newsroom/release/42441>
- 588 29 Pfas contamination in the Marinette and Peshtigo Area [Internet]. PFAS Contamination in the
589 Marinette and Peshtigo Area | Wisconsin DNR. Wisconsin Department of Natural
590 Resources; 2022 [cited 2023Jan17]. Available from:
591 <https://dnr.wisconsin.gov/topic/PFAS/Marinette.html>
- 592 30 Ankley GT, Lodge K, Call DJ, Balcer MD, Brooke LT, Cook PM, et al. Integrated
593 assessment of contaminated sediments in the Lower Fox River and Green Bay, Wisconsin.
594 *Ecotoxicology and Environmental Safety*. 1992;23(1):46–63.
- 595 31 Imamoglu I, Christensen ER. PCB sources, transformations, and contributions in recent Fox
596 River, Wisconsin sediments determined from receptor modeling. *Water Research*.
597 2002;36(14):3449–62.
- 598 32 Sullivan JR, Delfino JJ, Buelow CR, Sheffy TB. Polychlorinated biphenyls in the fish and
599 sediment of the Lower Fox River, Wisconsin. *Bulletin of Environmental Contamination*
600 *and Toxicology*. 1983;30(1):58–64.

- 601 33 Jha G, Kankarla V, McLennon E, Pal S, Sihi D, Dari B, et al. Per- and polyfluoroalkyl
602 substances (PFAS) in integrated crop–livestock systems: Environmental exposure and
603 human health risks. *International Journal of Environmental Research and Public Health*.
604 2021;18(23):12550.
- 605 34 Johnson GR. Pfas in soil and groundwater following historical land application of Biosolids.
606 *Water Research*. 2022;211:118035.
- 607 35 Water utility [Internet]. City of Madison, Wisconsin. [cited 2023Jan17]. Available from:
608 [https://www.cityofmadison.com/water/water-quality/water-quality-testing/perfluorinated-](https://www.cityofmadison.com/water/water-quality/water-quality-testing/perfluorinated-compounds)
609 [compounds](https://www.cityofmadison.com/water/water-quality/water-quality-testing/perfluorinated-compounds)
- 610 36 Staff AC. Wisconsin population increased 3.6% since 2010 [Internet]. Census.gov. United
611 States Census Bureau; 2021 [cited 2023Jan17]. Available from:
612 [https://www.census.gov/library/stories/state-by-state/wisconsin-population-change-](https://www.census.gov/library/stories/state-by-state/wisconsin-population-change-between-census-decade.html)
613 [between-census-decade.html](https://www.census.gov/library/stories/state-by-state/wisconsin-population-change-between-census-decade.html)
- 614 37 Malecki KM, Nikodemova M, Schultz AA, LeCaire TJ, Bersch AJ, Cadmus-Bertram L, et al.
615 The survey of the Health of Wisconsin (show) program: An infrastructure for advancing
616 population health. *Frontiers in Public Health*. 2022;10.
- 617 38 Minnesota Dept. of Public Health, Public Health Laboratory Division. Document DOC-563,
618 Detection of PFAS in serum and Plasma via LC-MS/MS. Unpublished methods.
- 619 39 Centers for Disease Control & Prevention, National Center for Environmental Health.
620 Laboratory Procedure manual NHANES 2015-16, method 6304.08. Perfluoroalkyl and
621 Polyfluoroalkyl Substances.
- 622 40 New York State Dept. of Health, Division of Environmental Health Sciences, Laboratory of
623 Organic Analytical Chemistry. Analysis of Perfluoroalkyl Substances In Human Serum by
624 Solid Phase Extraction and Ultra High Performance Liquid Chromatography Tandem Mass
625 Spectrometry. Unpublished methods.
- 626 41 Michigan Dept. of Community Health, Bureau of Laboratories. Document AC-54. Analysis
627 of serum for PFAS by RP-HPLC-MRM-MS/MS. 2018. Unpublished methods.
- 628 42 Centers for Disease Control and Prevention. Nhanes - about the National Health and Nutrition
629 Examination Survey. 2017. https://www.cdc.gov/nchs/nhanes/about_nhanes.htm
630 (accessed 2 May 2022).
- 631 43 Prior HHS Poverty Guidelines and Federal Register references [Internet]. ASPE. 2022 [cited
632 2023Jan17]. Available from: [https://aspe.hhs.gov/topics/poverty-economic-](https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines/prior-hhs-poverty-guidelines-federal-register-references)
633 [mobility/poverty-guidelines/prior-hhs-poverty-guidelines-federal-register-references](https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines/prior-hhs-poverty-guidelines-federal-register-references)

- 634 44 Yu CH, Riker CD, Lu S-en, Fan Z(T. Biomonitoring of emerging contaminants,
635 perfluoroalkyl and polyfluoroalkyl substances (PFAS), in New Jersey Adults in 2016–
636 2018. *International Journal of Hygiene and Environmental Health*. 2020;223(1):34–44.
- 637 45 Nair AS, Ma Z-qiang, Watkins SM, Wood SS. Demographic and exposure characteristics as
638 predictors of serum per- and polyfluoroalkyl substances (pfass) levels – a community-level
639 biomonitoring project in Pennsylvania. *International Journal of Hygiene and
640 Environmental Health*. 2021;231:113631.
- 641 46 Sagiv SK, Rifas-Shiman SL, Webster TF, Mora AM, Harris MH, Calafat AM, et al.
642 Sociodemographic and perinatal predictors of early pregnancy per- and polyfluoroalkyl
643 substance (PFAS) concentrations. *Environmental Science & Technology*.
644 2015;49(19):11849–58.
- 645 47 Wattigney WA, Savadatti SS, Liu M, Pavuk M, Lewis-Michl E, Kannan K, et al.
646 Biomonitoring of per- and polyfluoroalkyl substances in minority angler communities in
647 Central New York State. *Environmental Research*. 2022;204:112309.
- 648 48 Olsen GW, Mair DC, Lange CC, Harrington LM, Church TR, Goldberg CL, et al. Per- and
649 polyfluoroalkyl substances (PFAS) in American Red Cross Adult Blood Donors, 2000–
650 2015. *Environmental Research*. 2017;157:87–95.
- 651 49 Ding N, Harlow SD, Batterman S, Mukherjee B, Park SK. Longitudinal trends in
652 perfluoroalkyl and polyfluoroalkyl substances among multiethnic midlife women from
653 1999 to 2011: The study of women's health across the nation. *Environment International*.
654 2020;135:105381.
- 655 50 Evans GW, Kantrowitz E. Socioeconomic status and health: The potential role of
656 environmental risk exposure. *Annual Review of Public Health*. 2002;23(1):303–31.